Qubit Pharmaceuticals nominated for "Best start-up" award at Prix Galien USA 2024
19 Agosto 2024 - 10:00AM
Press Release
Qubit Pharmaceuticals nominated
for "Best start-up" award at Prix Galien USA
2024
- Qubit Pharmaceuticals has been
nominated for the 2024 edition of the prestigious Prix Galien USA,
in the "Best Startup" category, out of a field of 41 companies,
including 15 French contenders.- In November, the
company will be taking part in 2 days of networking in New York
with experts and key actors in the US healthcare sector, to promote
its technology and forge transatlantic partnerships.
Paris, 19 August 2024 - Qubit
Pharmaceuticals, a deeptech company specializing in the discovery
of new drug candidates through simulation and molecular modeling
accelerated by hybrid HPC and quantum computing, announces that it
has been nominated for the Prix Galien USA “Best Startup Award".
This nomination is in line with Qubit Pharmaceuticals' strategic
commitment to establishing and expanding its activities in North
America, a key market for biomedical and pharmaceutical
research.
Awarded by the Fondation Galien, the world's
leading institution for honoring innovators in the field of life
sciences, the Prix Galien is considered the equivalent of the Nobel
Prize in biopharmaceutical research. First introduced in France in
1970, the Prix Galien is now awarded in 17 countries, including the
United States since 2007. Each year, it recognizes outstanding
innovations that contribute to improving the quality of public
healthcare. Organized in partnership with Business France, the
Startup category, which is celebrating its tenth anniversary, is
designed to reward innovative French and international startups
with a strong societal impact that are collaborating with an
American entity in the Pharma, BioTech and Medtech fields. Prix
Galien USA aims to raise the profile of startups and promote
transatlantic partnerships with government, industry and
academia.
As a nominee, Qubit Pharmaceuticals will
participate in industry meetings, workshops and conferences around
the US healthcare ecosystem to explore potential strategies for
development in North America. The Startup Award ceremony will take
place on November 7 at the Museum of Natural History in New
York.
Robert Marino, CEO Qubit
Pharmaceuticals, states : "We are extremely pleased
to be nominated for this prestigious award. Beyond the sense of
pride, this recognition once again underlines the excellence of our
technology, and will be a powerful source of visibility in the U.S.
for potential international partnerships".
L’édition 2023 du Prix Galien
USA
Accelerating drug discovery with hybrid HPC and quantum
computing
With a team of 60 specialists in quantum
chemistry, computational chemistry, machine-learning and medicinal
chemistry, and thanks to the hybrid use of HPC (High Performance
Computing) supercomputers and quantum algorithms, Qubit
Pharmaceuticals has developed its revolutionary drug discovery
software platform, Atlas, which aims to reduce by a factor of 2 the
time needed to screen, select and optimize a drug candidate of
interest, and by a factor of more than 10 the investment required.
Qubit Pharmaceuticals manages a portfolio of 7 drug discovery
programs, with a focus on targets recognized as complex in fields
such as oncology and chronic inflammatory diseases. Qubit
Pharmaceuticals also has an innovative program focused on the
discovery of new treatments using RNA.
About Qubit
PharmaceuticalsQubit Pharmaceuticals was founded in 2020
with the vision of co-developing new, safer and more effective
drugs with pharmaceutical and biotech companies. A spin-off from
the research work of five internationally renowned scientists -
Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes
(CNAM), Jean-Philip Piquemal (Sorbonne University and CNRS), Jay
Ponder (Washington University in St Louis), Pengyu Ren (University
of Texas at Austin) - Qubit Pharmaceuticals leverages its Atlas
platform to discover new drugs through simulation and molecular
modeling accelerated by hybrid HPC and quantum computing. The
multidisciplinary team, led by CEO Robert Marino, and the founders
are based in France at the Paris Santé Cochin incubator and in the
USA in Boston.Qubit Pharmaceuticals has been named "Technology
Pioneer 2024" by the World Economic Forum, and has several
high-profile partnerships such as the Institut Curie, Sorbonne
University, and the Institute of Pharmacology at the University of
Sherbrooke in Canada.
For further information, including the drug
discovery portfolio, visit www.qubit-pharmaceuticals.com
About Galien FoundationThe
Fondation Galien encourages, recognizes and rewards excellence in
scientific innovation to improve the state of human health. Its
vision is to be the catalyst for the development of the next
generation of innovative, life-saving treatments and technologies.
The late Professor Elie Wiesel, winner of the Nobel Peace Prize in
1986, is Honorary Founding President of the Fondation Galien.The
Foundation oversees and directs activities in the United States for
the Prix Galien, an international awards program dedicated to
progress through the development of innovative treatments in 14
countries, Africa and an inaugural chapter established in India in
2024.The Prix Galien was created in 1970 by Roland Mehl in honor of
Galen, the father of modern medical science and pharmacology.
Worldwide, the Prix Galien is considered the equivalent of the
Nobel Prize in biopharmaceutical research.
About Galien Startup
AwardLaunched in France in 1970 and in the United States
in 2007, the Prix Galien is widely regarded as the equivalent of
the Nobel Prize in biopharmaceutical research. Each year, it
recognizes outstanding innovations that make a significant
contribution to improving public health. The Prix Galien USA
rewards innovations in 7 categories, via 2 selection committees
made up of eminent experts and specialists. The Startup category is
aimed at international startups collaborating with an American
entity in the Pharma, BioTech and Medtech fields. Its aim is
threefold:
1. Strengthen
partnerships between government, industry and
academia.2. Enhance
visibility with major American and international players
(committees & jury, investors,hospitals, associations, other
candidates,
etc.).3. Promote
transatlantic relations and encourage economic growth.
Media Contacts
Qubit PharmaceuticalsNicolas
Daniels – ndaniels@ulysse-communication.com – +33
(0)6.66.59.22.63Charles Courbet – ccourbet@ulysse-communication.com
- + 33 (0)6.28.93.03.06